

ASX Release

Anatara raises \$7 million, launches Share Purchase Plan to speed development of Detach™

Key points:

- **Capital raising oversubscribed by three times**
- **Strong support from existing and new institutional shareholders**
- **Launches Share Purchase Plan**
- **Funds to be used to further advance registration and development of Detach™**
- **Move into new markets faster**

BRISBANE, 3rd July 2015: Anatara Lifesciences (ASX:ANR) is pleased to announce it has raised \$7 million through a significantly oversubscribed capital raising to fund international registration and further development of its lead therapy, Detach™, a non-antibiotic, natural treatment to treat and prevent diarrhoea in pigs and other livestock animals.

Anatara has also announced a Share Purchase Plan that it will also offer each eligible shareholder the opportunity to subscribe for up to \$15,000 in Anatara shares.

Under the capital raising, around 9 million fully paid ordinary shares will be issued at a price of \$0.78 per share, a 19% discount to the 15 day VWAP.

The capital raising, aimed at wholesale, sophisticated and professional investors, was strongly supported by existing institutional shareholders.

Anatara Chief Executive Dr Paul Schober thanked investors for their commitment to the company and support for its strategic direction and future potential.

“We have a product that’s been shown to work and will meet a significant need for farmers around the world,” he said.

“The fund raising puts Anatara in a secure position as we continue discussions with global partners and will allow us to rapidly roll out Detach™ globally as we receive regulatory approvals.”

The funds raised will be used primarily to carry out parallel registration trials of Detach™ in Europe and the United States. Funds will also be used to ramp up manufacturing, safety studies, registration in Asia, proof of concept to use Detach™ in calves and poultry, and advance development of its use in humans.

As previously announced, a second field trial for Detach™ began in June, with the results expected in the third quarter of calendar 2015. Anatara expects Detach™ to be on sale in Australia within 12 months of lodging its regulatory approval application to the APVMA based on the pace of current progress.

Anatara Chairman Dr Mel Bridges said he was delighted by the strong response to the raising. “The Company has the ability to move into new markets and applications much faster than we had anticipated when Anatara was listed in October 2014. We have a responsibility to shareholders to take advantage of these opportunities and further add value.”

Pelaton Capital and Wilson HTM were the joint lead managers for the capital raising.

For more information please contact:

General inquiries

Dr Mel Bridges
Chairman, Anatara Lifesciences
+61 413051600
melbridges@parmacorp.com

Media inquiries

Gavin Lower
Buchan Consulting
03 8866 1215
glower@buchanwe.com.au

About Anatara Lifesciences

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.